Coinbase CEO’s Biotech Firm Secures $130M to Combat Aging Through AI and Genomics

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-05-07 04:21:01

NewLimit, a biotech startup co-founded by Coinbase CEO Brian Armstrong, has raised $130 million in a Series B funding round. The firm aims to extend healthy human lifespan using AI-driven cell reprogramming techniques. Kleiner Perkins led the investment, with participation from Founders Fund, Dimension Capital, and notable angel investors including Elad Gil and Stripe co-founder Patrick Collison.

The funding brings NewLimit’s total capital to over $170 million, positioning it among a growing cohort of longevity ventures backed by tech billionaires. The sector has gained traction as advances in genomics and machine learning converge to tackle age-related diseases.

By:

Log in to Reply

E-Commerce Firm Xcotton Co. Faces Class Action Over Unlicensed Warranty Services

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.